← FDA DRUG APPROVALS

FDA ANDA · ANDA077668

CITALOPRAM HYDROBROMIDE

Sponsor: PHARMOBEDIENT

APPLICATION
ANDA077668
TYPE
ANDA
ORIGINAL APPROVAL
2007-02-28
LATEST ACTION
2024-11-26
ROUTE
ORAL
DOSAGE FORM
CAPSULE
MARKETING STATUS
Discontinued

Products

CITALOPRAM HYDROBROMIDEDiscontinued
CITALOPRAM HYDROBROMIDE EQ 40MG BASE · CAPSULE · ORAL
CITALOPRAM HYDROBROMIDEDiscontinued
CITALOPRAM HYDROBROMIDE EQ 10MG BASE · CAPSULE · ORAL
CITALOPRAM HYDROBROMIDEDiscontinued
CITALOPRAM HYDROBROMIDE EQ 20MG BASE · CAPSULE · ORAL

Approval history

2024-11-26Labeling · Supplement 7 · standardAP
2014-07-17Labeling · Supplement 6 · standard — Label ↗AP
2009-04-06Labeling · Supplement 3AP
2009-02-13Labeling · Supplement 4AP
2008-09-24Labeling · Supplement 2AP
2007-10-22Labeling · Supplement 1AP
2007-02-28OriginalAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industry →GMP discipline →FDA drug shortages →FDA enforcement & recalls →

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →